cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30373536
title: Cancer-testis antigen ACRBP: Cytotoxic response to its HLA-A2 restricted peptide and immune features in ovarian cancer

description: While our prior study identified the HLA-A *0201-restricted ACRBP epitope peptide and demonstrated its capacity to generate cytotoxic T lymphocytes (CTLs) in vitro, the clinical relevance of the peptide-induced T cell reactivity in ovarian cancer (OC) patients and the in vivo anti-tumor efficacy of these CTLs remain unexplored. In this study, dendritic cells were sensitized with ACRBP peptide (ALLVLCYSI) and co-cultured with autologous CD8<sup>+</sup>T cells to induce the production of specific cytotoxic T lymphocytes (Pep-CTLs). The anti-tumor effects of Pep-CTLs were evaluated in SCID mice bearing human ovarian cancer (OC) OVCAR-3 cells. Concurrently, we co-cultured ALLVLCYSI peptide with peripheral blood mononuclear cells (PBMCs) from OC patients (HLA-A2<sup>+</sup>, ACRBP<sup>+</sup>) and assessed the number of specific T cells using ELISPOT assays. The immunological impact of the ACRBP peptide against human OC was validated through both in vitro and in vivo experiments. These findings establish a preclinical foundationfor developing ACRBP peptide-based vaccines in OC immunotherapy. To further elucidate ACRBP’s role in OC treatment, the study analyzed single-cell RNA sequencing data from 8 OC patients and bulk RNA sequencing data from the Cancer Genome Atlas Project (TCGA) comprising 308 ovarian cancer cases. This analysis aimed to explore the heterogeneity among ACRBP-expressing tumor cell populations and to investigate the correlation between ACRBP expression and immune molecule expression (including MHC and chemokines) alongside chemotherapy response. These insights furnish a theoretical framework supporting the future application of ACRBP in tumor immunotherapy and strategies to prevent immune escape.
DOI: 10.6084/m9.figshare.30373536.v1
title: Cancer-testis antigen ACRBP: Cytotoxic response to its HLA-A2 restricted peptide and immune features in ovarian cancer

description: While our prior study identified the HLA-A *0201-restricted ACRBP epitope peptide and demonstrated its capacity to generate cytotoxic T lymphocytes (CTLs) in vitro, the clinical relevance of the peptide-induced T cell reactivity in ovarian cancer (OC) patients and the in vivo anti-tumor efficacy of these CTLs remain unexplored. In this study, dendritic cells were sensitized with ACRBP peptide (ALLVLCYSI) and co-cultured with autologous CD8<sup>+</sup>T cells to induce the production of specific cytotoxic T lymphocytes (Pep-CTLs). The anti-tumor effects of Pep-CTLs were evaluated in SCID mice bearing human ovarian cancer (OC) OVCAR-3 cells. Concurrently, we co-cultured ALLVLCYSI peptide with peripheral blood mononuclear cells (PBMCs) from OC patients (HLA-A2<sup>+</sup>, ACRBP<sup>+</sup>) and assessed the number of specific T cells using ELISPOT assays. The immunological impact of the ACRBP peptide against human OC was validated through both in vitro and in vivo experiments. These findings establish a preclinical foundationfor developing ACRBP peptide-based vaccines in OC immunotherapy. To further elucidate ACRBP’s role in OC treatment, the study analyzed single-cell RNA sequencing data from 8 OC patients and bulk RNA sequencing data from the Cancer Genome Atlas Project (TCGA) comprising 308 ovarian cancer cases. This analysis aimed to explore the heterogeneity among ACRBP-expressing tumor cell populations and to investigate the correlation between ACRBP expression and immune molecule expression (including MHC and chemokines) alongside chemotherapy response. These insights furnish a theoretical framework supporting the future application of ACRBP in tumor immunotherapy and strategies to prevent immune escape.
DOI: 10.15468/dl.r75jjb
title: Occurrence Download

description: A dataset containing 121 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Guadeloupe",
 "OccurrenceStatus is Present",
 "TaxonKey is Protoneura romanae"
 ]
}

 The dataset includes 121 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032013-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30167774
title: Cost-effectiveness and public health impact of influenza vaccination strategies for Chinese patients with rheumatoid arthritis

description: Patients with rheumatoid arthritis (RA) are at higher risk of influenza than the general population, and influenza vaccination can effectively prevent infection in this group. We assessed the cost‑effectiveness of influenza vaccination for individuals with RA in China. We used a Markov model to project outcomes for several vaccination scenarios in hypothetical Chinese RA cohorts over five years. We quantified cases and deaths averted, quality‑adjusted life‑years (QALYs) gained, and incremental cost‑effectiveness ratios (ICERs) to identify the optimal vaccination strategy. Deterministic and probabilistic sensitivity analyses were conducted to assess model uncertainty. Compared with no vaccination, annual coverage levels of 2%, 30%, 60%, and 80% increased costs by US$230, US$165, US$96, and US$50 and yielded 0.006, 0.098, 0.198, and 0.064 additional QALYs, respectively. At 30% coverage, vaccination averted 203,199 influenza cases and yielded 0.49 million additional QALYs relative to no vaccination. Our findings remained robust across all sensitivity analyses. Influenza vaccination among RA patients in China was cost‑effective, with ICERs of US$38,312, US$1,687, US$486, and US$190 at coverage rates of 2%, 30%, 60%, and 80%, respectively. Increasing influenza vaccine coverage among individuals with RA is strongly recommended.
DOI: 10.6084/m9.figshare.30167774.v1
title: Cost-effectiveness and public health impact of influenza vaccination strategies for Chinese patients with rheumatoid arthritis

description: Patients with rheumatoid arthritis (RA) are at higher risk of influenza than the general population, and influenza vaccination can effectively prevent infection in this group. We assessed the cost‑effectiveness of influenza vaccination for individuals with RA in China. We used a Markov model to project outcomes for several vaccination scenarios in hypothetical Chinese RA cohorts over five years. We quantified cases and deaths averted, quality‑adjusted life‑years (QALYs) gained, and incremental cost‑effectiveness ratios (ICERs) to identify the optimal vaccination strategy. Deterministic and probabilistic sensitivity analyses were conducted to assess model uncertainty. Compared with no vaccination, annual coverage levels of 2%, 30%, 60%, and 80% increased costs by US$230, US$165, US$96, and US$50 and yielded 0.006, 0.098, 0.198, and 0.064 additional QALYs, respectively. At 30% coverage, vaccination averted 203,199 influenza cases and yielded 0.49 million additional QALYs relative to no vaccination. Our findings remained robust across all sensitivity analyses. Influenza vaccination among RA patients in China was cost‑effective, with ICERs of US$38,312, US$1,687, US$486, and US$190 at coverage rates of 2%, 30%, 60%, and 80%, respectively. Increasing influenza vaccine coverage among individuals with RA is strongly recommended.
DOI: 10.5281/zenodo.18713126
title: Product Characterization (NMR, HRMS, CHN, GCMS)

description: Data for the project/publication: Alkali-Metal Base Catalysed Electrocyclization of Isoprene Derivatives for Jet Fuel Precursors Synthesis
DOI: 10.48580/dgwqb.v1
title: Checklist of species indicated for Leningrad Oblast in Illyustrirovannyi Opredelitel Rasteniy Leningradskoy Oblasti (Averyanov et al., 2006): accepted names
DOI: 10.6084/m9.figshare.30061899
title: Correlation between the immune response to COVID-19 vaccines and the constitutions of traditional Chinese medicine

description: Traditional Chinese Medicine (TCM) classifies individuals into constitution types that may influence physiological responses. SARS-CoV-2 vaccines induce spike-specific antibodies and activate B and T cells, including memory subsets. This study investigates whether TCM constitution types are associated with immune responses and adverse events following COVID-19 vaccination. From March 2021 to December 2023, 78 adults received two doses of the COVID-19 vaccine, including AstraZeneca, Moderna, MVC-COV1901, and Pfizer-BioNTech. PBMCs were collected before and after vaccination. Immune parameters-cytokines, antibody titers, dendritic cells (DCs), T cells, B cells, and memory T cell subsets-were measured. TCM constitution scores were determined using the Constitution in Chinese Medicine Questionnaire (CCMQ) before vaccination. Adverse reactions were recorded through structured surveys, and correlations between constitution scores and adverse events were analyzed using the Pearson correlation. Pre-vaccination TNF-α was negatively correlated with the gentleness constitution and positively with the qi-deficiency. DCs increased post-vaccination in individuals with qi-deficiency, phlegm-dampness, qi-depression, yin-deficiency, dampness-heat, and special diathesis constitutions. T cell proportions increased in yin-deficiency, dampness-heat, and special diathesis groups. Dampness-heat scores were negatively correlated with central memory T cell (Tcm) induction. No significant correlations were found between constitution types and antibody levels or neutralization. Adverse reactions were more frequent in individuals with phlegm-dampness, qi-depression, and blood-stasis constitutions, and less frequent in those with a gentleness constitution. TCM constitutions correlate with cellular immune responses and adverse reaction profiles, but not antibody production, after COVID-19 vaccination. This supports integrating TCM constitution frameworks into personalized vaccine prediction.
DOI: 10.6084/m9.figshare.30061899.v1
title: Correlation between the immune response to COVID-19 vaccines and the constitutions of traditional Chinese medicine

description: Traditional Chinese Medicine (TCM) classifies individuals into constitution types that may influence physiological responses. SARS-CoV-2 vaccines induce spike-specific antibodies and activate B and T cells, including memory subsets. This study investigates whether TCM constitution types are associated with immune responses and adverse events following COVID-19 vaccination. From March 2021 to December 2023, 78 adults received two doses of the COVID-19 vaccine, including AstraZeneca, Moderna, MVC-COV1901, and Pfizer-BioNTech. PBMCs were collected before and after vaccination. Immune parameters-cytokines, antibody titers, dendritic cells (DCs), T cells, B cells, and memory T cell subsets-were measured. TCM constitution scores were determined using the Constitution in Chinese Medicine Questionnaire (CCMQ) before vaccination. Adverse reactions were recorded through structured surveys, and correlations between constitution scores and adverse events were analyzed using the Pearson correlation. Pre-vaccination TNF-α was negatively correlated with the gentleness constitution and positively with the qi-deficiency. DCs increased post-vaccination in individuals with qi-deficiency, phlegm-dampness, qi-depression, yin-deficiency, dampness-heat, and special diathesis constitutions. T cell proportions increased in yin-deficiency, dampness-heat, and special diathesis groups. Dampness-heat scores were negatively correlated with central memory T cell (Tcm) induction. No significant correlations were found between constitution types and antibody levels or neutralization. Adverse reactions were more frequent in individuals with phlegm-dampness, qi-depression, and blood-stasis constitutions, and less frequent in those with a gentleness constitution. TCM constitutions correlate with cellular immune responses and adverse reaction profiles, but not antibody production, after COVID-19 vaccination. This supports integrating TCM constitution frameworks into personalized vaccine prediction.
DOI: 10.6084/m9.figshare.28284383
title: Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

description: INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the occurrence of adverse events within 30 days after vaccination. A total of 781 volunteers were recruited and screened for eligibility, with 320 eligible young adults (≥18 to &lt;60 years old) and 320 elderly (≥60 to ≤85 years old) were randomly assigned to receive the low-dose (1.0 mg, <i>n</i> = 120) or high-dose (2.0 mg, <i>n</i> = 120) INO-4800, or placebo (<i>n</i> = 80). Notably, both dose groups exhibited significant increases in spike-binding antibodies at day 30 after the second dose, with GMTs of 1609.3 (95% CI: 1385.5–1869.3) for the low-dose group and 3016.7 (95% CI: 2577.4–3530.8) for the high-dose group. Additionally, both dose groups induced neutralizing antibodies against live SARS-CoV-2, with GMTs of 4.7 (95% CI: 4.2–5.3) and 6.6 (95% CI: 5.9–7.4) at day 30 after the second dose. The incidence of adverse events within 30 days after vaccination was slightly higher in the high-dose group (115 [47.9%]) than that in the low-dose group (105 [43.8%]) (<i>p</i> = .0060). All adverse reactions were grade 1 or 2, primarily occurring within 14 days after vaccination. No vaccine-related serious adverse events were reported. The COVID-19 DNA vaccine INO-4800 at two doses (1.0 mg or 2.0 mg) showed an acceptable safety profile and modest immunogenicity, with the high-dose slightly more immunogenic than the low-dose. <b>Clinical Trials Registration:</b>www.chictr.org.cn, identifier is ChiCTR2000040146.
DOI: 10.6084/m9.figshare.28284383.v1
title: Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

description: INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the occurrence of adverse events within 30 days after vaccination. A total of 781 volunteers were recruited and screened for eligibility, with 320 eligible young adults (≥18 to &lt;60 years old) and 320 elderly (≥60 to ≤85 years old) were randomly assigned to receive the low-dose (1.0 mg, <i>n</i> = 120) or high-dose (2.0 mg, <i>n</i> = 120) INO-4800, or placebo (<i>n</i> = 80). Notably, both dose groups exhibited significant increases in spike-binding antibodies at day 30 after the second dose, with GMTs of 1609.3 (95% CI: 1385.5–1869.3) for the low-dose group and 3016.7 (95% CI: 2577.4–3530.8) for the high-dose group. Additionally, both dose groups induced neutralizing antibodies against live SARS-CoV-2, with GMTs of 4.7 (95% CI: 4.2–5.3) and 6.6 (95% CI: 5.9–7.4) at day 30 after the second dose. The incidence of adverse events within 30 days after vaccination was slightly higher in the high-dose group (115 [47.9%]) than that in the low-dose group (105 [43.8%]) (<i>p</i> = .0060). All adverse reactions were grade 1 or 2, primarily occurring within 14 days after vaccination. No vaccine-related serious adverse events were reported. The COVID-19 DNA vaccine INO-4800 at two doses (1.0 mg or 2.0 mg) showed an acceptable safety profile and modest immunogenicity, with the high-dose slightly more immunogenic than the low-dose. <b>Clinical Trials Registration:</b>www.chictr.org.cn, identifier is ChiCTR2000040146.
DOI: 10.6084/m9.figshare.28140288
title: Factors determining first influenza vaccination among individuals with type 2 diabetes in the CONSTANCES cohort by age group (younger than 65 years or 65 and older)

description: Vaccine coverage against influenza is suboptimal among people with diabetes. Our principal objective was to study and compare the factors related to a first influenza vaccination in individuals with type 2 diabetes according to age group (&lt;65 years and ≥ 65 years) and then to compare the older age group with diabetes to the general population of that age. This is a descriptive cross-sectional study within the French Constances cohort. The study populations were composed of people with type 2 diabetes and individuals without diabetes 65 years and older. Our variable of interest was the first reimbursement for a vaccine against influenza over the period from 2009 to 2019. We identified 2540 cohort members with type 2 diabetes (&lt;65 years <i>n</i> = 1583; ≥65 years <i>n</i> = 957). The population without diabetes (≥65 years) comprised 18,364 individuals. The factors related to the first influenza vaccination differed significantly between the persons with diabetes younger than 65 years and those aged at least 65 years: age (OR = 1.01/OR = 0.89—<i>P-interaction</i>&lt;0.001), poor perceived health (OR = 1.24/OR = 0.79—<i>P-interaction</i> = 0.048), and indicators of diabetes treatment quality [at least 2 hbA1c assays/year (OR = 1.91/0 R = 0.90—<i>P-interaction</i>&lt;0.001), and blood pressure &lt; 140/90 (OR = 1.24/OR = 0.90—<i>P-interaction</i> = 0.059)]. The only factor related to first influenza vaccination significantly different between individuals aged at least 65 years with and without diabetes was age (OR = 0.83/OR = 1.05—<i>P-interaction</i>&lt;0.001). This study shows that trials are now needed to test the effectiveness of age- and sex-specific messages to increase influenza vaccination coverage among people with diabetes.
DOI: 10.6084/m9.figshare.28140288.v1
title: Factors determining first influenza vaccination among individuals with type 2 diabetes in the CONSTANCES cohort by age group (younger than 65 years or 65 and older)

description: Vaccine coverage against influenza is suboptimal among people with diabetes. Our principal objective was to study and compare the factors related to a first influenza vaccination in individuals with type 2 diabetes according to age group (&lt;65 years and ≥ 65 years) and then to compare the older age group with diabetes to the general population of that age. This is a descriptive cross-sectional study within the French Constances cohort. The study populations were composed of people with type 2 diabetes and individuals without diabetes 65 years and older. Our variable of interest was the first reimbursement for a vaccine against influenza over the period from 2009 to 2019. We identified 2540 cohort members with type 2 diabetes (&lt;65 years <i>n</i> = 1583; ≥65 years <i>n</i> = 957). The population without diabetes (≥65 years) comprised 18,364 individuals. The factors related to the first influenza vaccination differed significantly between the persons with diabetes younger than 65 years and those aged at least 65 years: age (OR = 1.01/OR = 0.89—<i>P-interaction</i>&lt;0.001), poor perceived health (OR = 1.24/OR = 0.79—<i>P-interaction</i> = 0.048), and indicators of diabetes treatment quality [at least 2 hbA1c assays/year (OR = 1.91/0 R = 0.90—<i>P-interaction</i>&lt;0.001), and blood pressure &lt; 140/90 (OR = 1.24/OR = 0.90—<i>P-interaction</i> = 0.059)]. The only factor related to first influenza vaccination significantly different between individuals aged at least 65 years with and without diabetes was age (OR = 0.83/OR = 1.05—<i>P-interaction</i>&lt;0.001). This study shows that trials are now needed to test the effectiveness of age- and sex-specific messages to increase influenza vaccination coverage among people with diabetes.
DOI: 10.6084/m9.figshare.29525279
title: Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study

description: Pneumococcal disease (PD) is associated with high morbidity and mortality, specifically among individuals ≥65 years of age and those with underlying medical conditions (UMCs). This retrospective cohort study estimated the clinical burden of PD in adults ≥18 years of age with or without UMCs in France. Data were obtained from the French National Health Data System for four yearly cohorts (1 January 2015–31 December 2018). Characteristics of patients with UMCs, with or without PD (UMC population), and the incidence rate and lethality rate of PD leading to hospitalization (in-patient PD population), stratified by age and risk status, were described. In the UMC population (<i>n</i> = 7,947,622; mean age: 65 years), the incidence rate of in-patient PD episodes was 121.98 per 100,000 person-years and was highest among individuals ≥65 years of age (138.52) and in those considered medium-risk (102.45) or high-risk (165.77). In the in-patient PD population (<i>n</i> = 41,885), 59.6% were ≥65 years of age; 1-year all-cause mortality following the initial in-patient PD episode was 26.5%. Individuals ≥65 years of age (regardless of risk status) had a higher risk of PD leading to hospitalization than individuals 18–64 years of age. This study shows a high burden of PD in France due to in-patient PD among adults with UMCs, particularly in those ≥65 years of age, despite their eligibility for pneumococcal vaccination. This highlights the need for higher vaccination coverage, supported by the recent extension of vaccination to all people ≥65 years of age, regardless of their health risk status.